NZ741086B2 - Compositions and methods for inhibiting gene expression of lpa - Google Patents
Compositions and methods for inhibiting gene expression of lpa Download PDFInfo
- Publication number
- NZ741086B2 NZ741086B2 NZ741086A NZ74108616A NZ741086B2 NZ 741086 B2 NZ741086 B2 NZ 741086B2 NZ 741086 A NZ741086 A NZ 741086A NZ 74108616 A NZ74108616 A NZ 74108616A NZ 741086 B2 NZ741086 B2 NZ 741086B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- sequence
- rnai agent
- rza
- lpa rnai
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims abstract 43
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract 43
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims abstract 42
- 239000003795 chemical substances by application Substances 0.000 claims abstract 41
- 239000003814 drug Substances 0.000 claims abstract 4
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims abstract 2
- 101150091521 lpa gene Proteins 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000000692 anti-sense effect Effects 0.000 claims 27
- 108091081021 Sense strand Proteins 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 8
- 230000008685 targeting Effects 0.000 claims 5
- BXJSAMKIFDDLGI-UHFFFAOYSA-N 2-(dimethylamino)-N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]benzamide Chemical compound COc1ccc(cc1S(=O)(=O)Nc1cccc(NCCNC(=O)c2ccccc2N(C)C)c1)-c1cccc(c1)C(=O)N(C)C BXJSAMKIFDDLGI-UHFFFAOYSA-N 0.000 claims 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 208000035657 Abasia Diseases 0.000 claims 1
- 101100239890 Candida albicans (strain SC5314 / ATCC MYA-2876) NAG4 gene Proteins 0.000 claims 1
- 101001024442 Cellulomonas fimi Beta-N-acetylglucosaminidase/beta-glucosidase Proteins 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 150000002256 galaktoses Chemical class 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
Abstract
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
Claims (33)
1. An LPA RNA interference (RNAi) agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises the sequence of any one of SEQ ID NO:1280, SEQ ID NO:1282, SEQ ID NO:1246, SEQ ID NO:1242, SEQ ID NO:1244, or SEQ ID 5 NO:1254, and wherein the sense strand comprises a sequence that is complementary to the sequence of the antisense strand.
2. The LPA RNAi agent of claim 1, wherein the sense strand and antisense strand are each 19 to 26 nucleotides in length.
3. The LPA RNAi agent of claim 2, wherein the sense strand and antisense strand are each 21 nucleotides in length.
4. The LPA RNAi agent of any one of claims 1 to 3, wherein the LPA RNAi agent 15 comprises one or two overhangs.
5. The LPA RNAi agent of claim 4, wherein the LPA RNAi agent comprises an overhang at the 3' end of the antisense . 20
6. The LPA RNAi agent of claim 4, wherein the LPA RNAi agent comprises an ng at the 3' end of the antisense strand and an overhang at the 3' end of the sense strand.
7. The LPA RNAi agent of any one of claims 1 to 3, wherein the LPA RNAi agent 25 comprises one or two blunt ends.
8. The LPA RNAi agent of claim 7, wherein the LPA RNAi agent comprises two blunt ends. 30
9. The LPA RNAi agent of any one of claims 1 to 8, wherein the sense strand, the antisense , or both the sense and antisense strand comprise one or more modified nucleotides.
10. The LPA RNAi agent of claim 9, wherein the one or more modified nucleotides are None set by rza MigrationNone set by rza Unmarked set by rza None set by rza MigrationNone set by rza Unmarked set by rza independently selected from a 2'-modified nucleotide, a locked nucleotide, an abasic nucleotide, an inverted deoxynucleotide, a morpholino nucleotide, a 2',3'-seco nucleotide mimic, or a nucleotide containing a non-natural base. 5
11. The LPA RNAi agent of claim 10, wherein the 2'-modified nucleotide is a 2'-O- methyl nucleotide, a 2'-deoxy-2'-fluoro nucleotide, a 2'-deoxynucleotide, a 2'-methoxyethyl nucleotide, a 2'-amino nucleotide, or a 2'-alkyl nucleotide.
12. The LPA RNAi agent of any one of claims 1 to 11, wherein the LPA RNAi agent 10 comprises one or more phosphorothioate internucleoside linkages.
13. The LPA RNAi agent of claim 12, n both the sense and nse strand independently comprise 1, 2, 3, or 4 phosphorothioate internucleoside linkages. 15
14. The LPA RNAi agent of any one of claims 1 to 13, wherein the LPA RNAi agent r comprises a targeting group.
15. The LPA RNAi agent of claim 14, wherein the targeting group comprises an asialoglycoprotein receptor ligand.
16. The LPA RNAi agent of claim 15, wherein the asialoglycoprotein receptor ligand comprises galactose, osamine, yl-galactosamine, or a galactose derivative.
17. The LPA RNAi agent of claim 14, wherein the ing group is (Chol-TEG), (TEG- 25 Chol), (C11-PEG3-NAG3), (C6-PEG4-NAG3), (NAG3), (NAG4), (NAG3-AA2), (NAG3- Palm), ), ), (NAG24), (NAG25), (NAG25)s, (NAG26), (NAG27), (NAG28), (NAG29), (NAG30) (NAG30)s, (NAG31), (NAG31s), (NAG32), ), (NAG34), (NAG35), (NAG36), or (NAG37). 30
18. The LPA RNAi agent of claim 17, wherein the targeting group comprises: None set by rza MigrationNone set by rza Unmarked set by rza None set by rza ionNone set by rza Unmarked set by rza n NAG is N-Acetyl-Galactosamine and X is selected from the group consisting of O and S. 5
19. The LPA RNAi agent of any one of claims 14 to 18, wherein the targeting group is conjugated to the 3' end of the sense strand.
20. The LPA RNAi agent of any one of claims 14 to 18, wherein the targeting group is ated to the 5' end of the sense strand.
21. The LPA RNAi agent of any one of claims 1 to 20, wherein: a) the antisense strand comprises the sequence of SEQ ID NO:1280 and the sense strand comprises the sequence of SEQ ID NO:1284; b) the antisense strand comprises the sequence of SEQ ID 6 and the sense 15 strand ses the sequence of SEQ ID NO:1247; c) the antisense strand comprises the sequence of SEQ ID NO:1242 and the sense strand comprises the sequence of SEQ ID NO:1243; d) the antisense strand comprises the sequence of SEQ ID NO:1244 and the sense strand comprises the sequence of SEQ ID NO:1245; 20 e) the antisense strand ses the sequence of SEQ ID NO:1254 and the sense strand comprises the sequence of SEQ ID NO:1255; f) the antisense strand comprises the sequence of SEQ ID NO:1280 and the sense strand comprises the sequence of SEQ ID NO:1260; or g) the antisense strand comprises the sequence of SEQ ID NO:1282 and the sense None set by rza MigrationNone set by rza Unmarked set by rza None set by rza ionNone set by rza ed set by rza strand comprises the sequence of SEQ ID NO:1259.
22. The LPA RNAi agent of any one of claims 1 to 21, wherein: a) the antisense strand comprises the ce of SEQ ID NO:188 and the sense 5 strand comprises the sequence of SEQ ID NO:384; b) the antisense strand comprises the sequence of SEQ ID NO:156 and the sense strand ses the sequence of SEQ ID ; c) the antisense strand comprises the sequence of SEQ ID NO:164 and the sense strand comprises the sequence of SEQ ID NO:357; 10 d) the antisense strand comprises the sequence of SEQ ID NO:164 and the sense strand comprises the sequence of SEQ ID NO:376; or e) the antisense strand comprises the sequence of SEQ ID NO:164 and the sense strand comprises the sequence of SEQ ID NO:384. 15 23. The LPA RNAi agent of claim 22, wherein the antisense strand comprises the sequence of SEQ ID NO:188 and the sense strand comprises the sequence of SEQ ID
23.NO:384.
24. The LPA RNAi agent of any one of claims 1 to 23, wherein: 20 a) the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 790 and the sense strand ses the sequence of modified nucleotides according to SEQ ID NO: 1189; b) the nse strand comprises the sequence of modified nucleotides according to SEQ ID NO: 637 and the sense strand comprises the ce of modified nucleotides 25 according to SEQ ID NO: 1132; c) the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 709 and the sense strand comprises the sequence of ed nucleotides according to SEQ ID NO: 1135; d) the antisense strand comprises the sequence of ed nucleotides according to 30 SEQ ID NO: 787 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1191; or e) the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 788 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1189. None set by rza MigrationNone set by rza Unmarked set by rza None set by rza MigrationNone set by rza Unmarked set by rza
25. The LPA RNAi agent of claim 24, wherein the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 790 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1189.
26. A pharmaceutical composition comprising the LPA RNAi agent of any one of claims 1 to 25 and a pharmaceutically acceptable excipient.
27. Use of the LPA RNAi agent of any one of claims 1 to 25 in the cture of a 10 medicament for inhibiting LPA gene expression in a subject in need thereof.
28. The use of claim 27, n the subject has or is at risk of having cardiovascular disease. 15
29. Use of the LPA RNAi agent of any one of claims 1 to 25 in the manufacture of a medicament for treating cardiovascular disease in a subject in need thereof.
30. Use of the LPA RNAi agent of any one of claims 1 to 25 in the manufacture of a medicament for reducing Lp(a) serum levels in a subject in need thereof.
31. The LPA RNAi agent according to any one of claims 1 to 25, substantially as herein described with reference to any one or more of the examples but ing ative 25
32. The pharmaceutical ition according to claim 26, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
33. The use according to any one of claims 27 to 30, substantially as herein described 30 with reference to any one or more of the examples but excluding comparative examples. None set by rza MigrationNone set by rza Unmarked set by rza None set by rza MigrationNone set by rza Unmarked set by rza 132-WO-PCT_112016_
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235816P | 2015-10-01 | 2015-10-01 | |
| US201662346304P | 2016-06-06 | 2016-06-06 | |
| US201662383221P | 2016-09-02 | 2016-09-02 | |
| PCT/US2016/054729 WO2017059223A2 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for inhibiting gene expression of lpa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ741086A NZ741086A (en) | 2023-11-24 |
| NZ741086B2 true NZ741086B2 (en) | 2024-02-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290566B1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| US20180087055A1 (en) | Modified tgf-beta2 oligonucleotides | |
| CN106535917B (en) | Compositions and methods for inhibiting alpha-1 antitrypsin gene expression | |
| JP2018529732A5 (en) | ||
| MX2019005816A (en) | Modified rna agents with reduced off-target effect. | |
| JP2022106727A (en) | Modulators of diacylglycerol acyltransferase 2 (dgat2) | |
| JP2021506238A5 (en) | ||
| EP3122889B1 (en) | Una oligomers having reduced off-target effects in gene silencing | |
| WO2017079291A1 (en) | Compounds and methods for modulating c90rf72 | |
| WO2008109452B1 (en) | Nucleic acid compounds for inhibiting tie gene expression and uses thereof | |
| WO2007134161A3 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| TW201536329A (en) | Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression | |
| PT2015758E (en) | Compounds and methods for modulating expression apob | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| JP2016520312A5 (en) | ||
| US20230113497A1 (en) | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION | |
| JP2013511984A (en) | Minor groove binder (MGB)-oligonucleotide miRNA antagonist | |
| JP2017510583A (en) | Transthyretin allele-selective UNA oligomers for gene silencing | |
| FR2790757B1 (en) | OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| TW202020152A (en) | Oligonucleotides for modulating rtel1 expression | |
| NZ741086B2 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| US10519447B2 (en) | Therapeutic UNA oligomers and uses thereof | |
| Li et al. | Advances in structural-guided modifications of siRNA | |
| KR20240110595A (en) | Stabilized RNA preparations | |
| JP2021511022A (en) | Oligonucleotides for regulating PIAS4 expression |